Drug profile · INN
fomivirsen
VITRAVENE
fomivirsen (VITRAVENE) is a major intermediate early region 2 mrna antisense inhibitor.
EMA: withdrawn Sensory organs (S01) S01AD08
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — fomivirsen
- Class
- Sensory organs (S01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
fomivirsen (VITRAVENE) is a major intermediate early region 2 mrna antisense inhibitor.
Key facts
INN fomivirsen
Brand VITRAVENE
Mechanism Major intermediate early region 2 mRNA antisense inhibitor
Target Major intermediate early region 2 mRNA
Therapeutic class Sensory organs (S01)
ATC code S01AD08
Mechanism of action
Major intermediate early region 2 mRNA antisense inhibitor
Primary target: Major intermediate early region 2 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fomivirsen?
fomivirsen (VITRAVENE) is a major intermediate early region 2 mrna antisense inhibitor.
What is the brand name for fomivirsen?
VITRAVENE is a marketed brand name for fomivirsen. Check FDA Drugs@FDA for the current US label holder and prescribing information.